FilingSEC EDGAR8-K
Editas Medicine Receives Approval to Initiate Phase 1/2 Clinical Trial of EDIT-401
· SEC accepted
StagePhase 1/2
Filing content
The company received approval to initiate the Phase 1/2 Strive clinical trial of EDIT-401 in Australia and expects to report initial safety data in the first quarter of 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…